Descripción de la empresa
Ionis Pharmaceuticals, Inc. operates as a commercial-stage biotechnology entity dedicated to the development and provision of RNA-targeted medicines primarily within the United States market. The company functions within the Healthcare sector and specifically the Biotechnology industry, a segment characterized by high capital expenditure requirements and reliance on proprietary intellectual property for competitive advantage. The scale of the organization is substantial, with a total market capitalization of $11.92B and an annual revenue of $943.71M, supported by a workforce of 1402 employees. These valuation figures indicate that the market assigns a significant premium to the company's pipeline, reflecting expectations for future commercial success despite current profitability challenges, while the revenue level suggests a mature stage of product commercialization rather than early-stage exploration.
Salud financiera
The company reported a trailing twelve-month revenue of $943.71M, yet generated a net income of -$381,387,008 and an EBITDA of -$369,236,992. The substantial disparity between positive revenue and significant negative net income reveals a cost structure where operating expenses and research costs far exceed current earnings, a typical characteristic of biopharmaceutical firms in the commercial stage. Free cash flow stands at -$154,724,496, indicating that the company is currently burning cash to fund operations and development, which limits immediate financial flexibility for external expansion without further capital raising. Profitability metrics are strained across the board, with a gross margin of 1.3%, an operating margin of -105.5%, and a profit margin of -40.4%, signaling that cost of goods sold is high relative to sales and that the business model is not yet self-sustaining. The balance sheet shows a cash position of $2.68B against total debt of $2.62B, resulting in a debt-to-equity ratio of 534.84, which suggests a highly leveraged capital structure where equity is minimal relative to obligations. Despite this leverage, the current ratio of 3.83 indicates strong short-term liquidity, as the company holds sufficient current assets to cover its current liabilities more than three times over. Return on Equity is -70.8% and Return on Assets is -7.3%, metrics that reveal that management has not yet generated positive returns on the capital invested in the company's assets or shareholder equity.
Evaluación de valoración
Valuation multiples for Ionis are distorted by the lack of profitability, showing a P/E Ratio (TTM) as N/A and a Forward P/E of -115.98. The negative forward P/E implies that analysts or the market is pricing in a trajectory where earnings are expected to remain negative in the near term, preventing a meaningful trailing multiple comparison. The price-to-book ratio sits at 24.09, indicating that the market values the company at a significant premium of over 24 times its net asset book value, likely driven by the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 12.63 and an EV/EBITDA of -32.10 further highlight that investors are pricing the stock based on sales growth prospects rather than current earnings power or earnings quality. The stock has traded between a 52-week low of $23.95 and a 52-week high of $86.74, meaning the current price sits in a wide range relative to recent historical volatility. The beta of 0.36 suggests that the stock exhibits low price volatility, moving with less intensity than the broader market index, which provides a different risk profile compared to typical large-cap pharmaceutical peers.
Growth & Income
Revenue growth year-over-year is -10.3%, while earnings growth is N/A due to the lack of reported earnings in the trailing twelve-month period. Since earnings are negative, they are technically growing or contracting relative to revenue, but the lack of a positive earnings base makes the standard earnings growth metric inapplicable for comparison. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is retained to fund ongoing operations and research rather than being distributed to shareholders. This reinvestment strategy is standard for biotechnology companies that must prioritize capital allocation toward pipeline advancement over shareholder returns. The overall growth and income profile is defined by revenue contraction in the recent period and a complete absence of dividend income, reflecting a capital-intensive growth stage focused on product approval and commercialization rather than financial returns.